Management of Metabolic-Associated Fatty Liver Disease

Venkatesan, Kirthika; Haroon, Nisha Nigil

doi:10.1016/j.ecl.2023.02.002

Cited by 4 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, changing dietary habits and lifestyle has shown positive results in the treatment of fatty liver and is free of side effects . Some studies emphasize the importance of minimizing the intake of high-sugar and high-fat foods as much as possible .…”

Section: Types Of Liver Diseasesmentioning

confidence: 99%

“…121,122 To date, changing dietary habits and lifestyle has shown positive results in the treatment of fatty liver and is free of side effects. 123 Some studies emphasize the importance of minimizing the intake of high-sugar and high-fat foods as much as possible. 124 The adoption of a mediterranean diet (MED) or a low-carbohydrate diet can be an effective alternative to reduce the likelihood of liver fat degeneration.…”

Section: Types Of Liver Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left−right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.

show abstract

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…48 No drugs have been approved by the United States Food and Drug Administration for MAFLD at this stage; nonetheless, a few drugs, including obeticholic acid, elafibranor and selonsertib, have progressed to phase III development, showing evidence of reducing NASH and fibrosis. [49][50][51][52] Several antidiabetic touchREVIEWS in Endocrinology and antiobesity medications can be effectively used in patients with MAFLD, especially when patients have these comorbidities. 47 Epidemiological studies and Mendelian randomization studies have shown NAFLD/MAFLD to be a significant cardiovascular disease (CVD) risk factor, similarly to the CVD risk associated with diabetes mellitus.…”

mentioning

confidence: 99%

Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action

Fernandez,

Nagendra,

Pappachan

2023

touchREVIEWS in Endocrinology

View full text Add to dashboard Cite

There has been an exponential increase in the global prevalence of fatty liver disease in recent years in association with the obesity pandemic worldwide. 'Metabolic dysfunction-associated fatty liver disease', the new terminology adopted by an international panel of experts in 2020 to largely replace the old term 'non-alcoholic fatty liver disease', has now been accepted by most hepatologists and diabetologists across the globe. The term metabolic dysfunction-associated fatty liver disease was created to better reflect the metabolicand liver-specific manifestations and complications of fatty liver disease. It is important to disseminate our current understanding of this enigmatic disease among the global scientific fraternity. Recent publications, including articles from the latest issue of Endocrinology & Metabolism Clinics of North America, are attempting to fill this knowledge gap.

show abstract

The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men

Bin,

Liu,

Peng

et al. 2024

Nutr. Diabetes

View full text Add to dashboard Cite

Objectives The present study aimed to investigate the relationship between male hormones and metabolic dysfunction-associated fatty liver disease (MAFLD) in males. Methods Data from the Fangchenggang Area Male Health and Examination Survey (FAMHES) were used to analyze the male hormone levels between MAFLD patients and controls. Univariate and multivariate logistic regression analyses were performed to identify risk factors for MAFLD. Receiver operating characteristic curve analysis was used to assess the diagnostic performance of male hormones for MAFLD. Result A total of 1578 individuals were included, with 482 individuals (30.54%) of MAFLD, including 293 (18.57%) with mild disease and 189 (11.98%) with moderate-to-severe disease. The MAFLD patients were significantly older than those without MAFLD. The LH, FSH, and SHBG levels in the MAFLD patients were significantly greater than those in the control group. Age, FSH, LH, SHBG, and estradiol were all risk factors for MAFLD. Age, FSH, and LH were risk factors for moderate-to-severe MAFLD. FSH was an independent risk factor for MAFLD and moderate-to-severe MAFLD. FSH showed an excellent diagnostic value, with an AUC of 0.992 alone and 0.996 after adjusting age. Conclusions Our findings indicate that FSH may be a potential diagnostic and predictive biomarker for MAFLD.

show abstract

Management of Metabolic-Associated Fatty Liver Disease

Cited by 4 publications

References 33 publications

Emerging mRNA Technology for Liver Disease Therapy

Emerging mRNA Technology for Liver Disease Therapy

Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action

The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men

Contact Info

Product

Resources

About